Artal Group’s Amicus Therapeutics FOLD Stock Holding History

Artal Group’s Portfolio FOLD Stock Details FOLD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-1,011,776	Closed	-$11.9M	–	121
2024 Q1	$11.9M	Sell	1,011,776 -1,014,588	-50%	-$13M	0.3%	40
2023 Q4	$28.8M	Sell	2,026,364 -2,036,203	-50%	-$23.1M	0.96%	17
2023 Q3	$49.4M	Sell	4,062,567 -500,000	-11%	-$6.45M	2.12%	8
2023 Q2	$57.3M	Buy	4,562,567 +1,036,160	+29%	+$12.3M	1.78%	10
2023 Q1	$39.1M	Sell	3,526,407 -473,593	-12%	-$5.84M	2.32%	13
2022 Q4	$48.8M	Hold	4,000,000	–	–	2.73%	10
2022 Q3	$41.8M	Hold	4,000,000	–	–	1.78%	18
2022 Q2	$43M	Hold	4,000,000	–	–	2.29%	13
2022 Q1	$37.9M	Sell	4,000,000 -2,000,000	-33%	-$18.8M	1.59%	16
2021 Q4	$69.3M	Sell	6,000,000 -696,955	-10%	-$7.77M	1.88%	12
2021 Q3	$64M	Buy	6,696,955 +2,946,955	+79%	+$30.1M	1.43%	18
2021 Q2	$36.1M	Hold	3,750,000	–	–	0.73%	30
2021 Q1	$37M	Buy	3,750,000 +1,250,000	+50%	+$19.3M	0.65%	37
2020 Q4	$57.7M	Sell	2,500,000 -500,000	-17%	-$10.2M	1.24%	22
2020 Q3	$42.4M	Sell	3,000,000 -500,000	-14%	-$7.29M	1.03%	25
2020 Q2	$52.8M	Sell	3,500,000 -1,500,000	-30%	-$18.3M	1.48%	16
2020 Q1	$46.2M	Buy	5,000,000 +2,000,000	+67%	+$19M	1.95%	14
2019 Q4	$29.2M	Buy	3,000,000 +500,000	+20%	+$4.58M	1.13%	18
2019 Q3	$20.1M	Hold	2,500,000	–	–	0.8%	23
2019 Q2	$31.2M	Sell	2,500,000 -100,000	-4%	-$1.27M	1.26%	18
2019 Q1	$35.4M	Sell	2,600,000 -400,000	-13%	-$4.89M	1.44%	19
2018 Q4	$28.7M	Sell	3,000,000 -1,000,000	-25%	-$11M	1.06%	20
2018 Q3	$48.4M	Buy	4,000,000 +1,100,000	+38%	+$15.4M	1.26%	15
2018 Q2	$45.3M	Buy	2,900,000 +400,000	+16%	+$6.05M	0.96%	14
2018 Q1	$37.6M	Buy	2,500,000 +1,500,000	+150%	+$22.8M	0.47%	22
2017 Q4	$14.4M	Buy	1,000,000 +300,000	+43%	+$4.12M	0.22%	39
2017 Q3	$10.6M	Sell	700,000 -700,000	-50%	-$9.26M	0.18%	40
2017 Q2	$14.1M	Sell	1,400,000 -500,000	-26%	-$4.02M	0.25%	29
2017 Q1	$13.5M	Buy	1,900,000 +150,000	+9%	+$948K	0.3%	29
2016 Q4	$8.7M	Sell	1,750,000 -150,000	-8%	-$1.04M	0.19%	39
2016 Q3	$14.1M	Buy	1,900,000 +650,000	+52%	+$4.39M	0.28%	32
2016 Q2	$6.83M	Buy	+1,250,000	New	+$8.74M	0.14%	36

Other funds holding FOLD

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Artal Group's FOLD Position: Q2 2024 in Review

Artal Group sold out of Amicus Therapeutics (FOLD) in Q2 2024, closing a stake of 1,011,776 shares — an estimated $11.9M sold.

Artal Group first reported a position in FOLD in Q2 2016 and held it in 32 quarters. The position peaked at $69.3M in Q4 2021. 258 funds tracked by Wall St. Rank hold FOLD as of Q2 2024.

Artal Group reported no remaining Amicus Therapeutics position as of Q2 2024 after selling out during the quarter.
Artal Group sold 1,011,776 Amicus Therapeutics shares in Q2 2024, an estimated $11.9M.
Artal Group first reported a position in Amicus Therapeutics in Q2 2016 and held it in 32 quarters.
Artal Group's Amicus Therapeutics position peaked at $69.3M in Q4 2021.
258 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q2 2024.

Based on Artal Group's 13F filing for Q2 2024, filed 14 Aug 2024.